U.S. Personal Products Stock News

Paychex Director Joseph Doody recently acquired additional shares of NasdaqGS:PAYX, signaling increased personal exposure to the company. The insider purchase comes as Paychex shares trade at $91.24 following a 16.0% decline year to date. This transaction adds a fresh data point for investors watching insider activity at Paychex. For investors tracking Paychex, the timing of this insider buying stands out against a weaker recent share performance. The stock is at $91.24, with a 7 day return...

Earlier in February 2026, Albemarle said it had idled the last operating train at its Kemerton lithium hydroxide plant in Western Australia, recorded US$245.60 million of long‑lived asset impairments for the December 2025 quarter, and reported a quarterly net loss despite higher sales. At the same time, Albemarle guided to 2026 net sales of US$5.70 billion to US$6.00 billion with flat volumes, while shifting Kemerton into care and maintenance but planning to meet lithium hydroxide demand...

Voya Financial (VOYA) has launched a new fixed income offering of senior, unsecured fixed rate notes, shortly after filing an omnibus shelf registration that covers debt, equity, preferred stock, depositary shares, warrants, and units. See our latest analysis for Voya Financial. Voya’s new notes come after a period where momentum has softened slightly in the short term, with a 30 day share price return of a 1.83% decline. The 1 year total shareholder return of 6.56% and 5 year total...

If you are wondering whether Regeneron Pharmaceuticals is still priced fairly after a strong multi year run, or if the market is missing something in plain sight, this article will help you weigh what you are really paying for. The stock most recently closed at US$779.67, with returns of 3.5% over 30 days and 74.2% over 5 years, so recent moves and longer term performance give mixed signals on how the market is pricing its potential and risks. Recent headlines around Regeneron have focused...

Liberty Global Ltd. has reported its full-year 2025 results, with sales rising to US$4,878.5 million from US$4,341.9 million, but swinging from a net income of US$1.59 billion to a very large net loss of US$7.14 billion and a basic loss per share from continuing operations of US$20.86. The combination of higher revenue and a very large reported loss raises questions about cost structure, one-off charges, and how resilient the business model really is. We’ll now consider how this sharp move...

Insmed (INSM) has been in focus after its fourth quarter and full year 2025 earnings, where strong revenue from ARIKAYCE and new drug BRINSUPRI contrasted with a wider net loss and ambitious 2026 sales guidance. See our latest analysis for Insmed. Insmed’s recent earnings and guidance have come alongside a sharp move in the share price, with a 10.86% 7 day share price return and 5.57% 30 day share price return partly offsetting a 21.10% 90 day share price decline. The 1 year total shareholder...

If you are wondering whether CONMED's current share price reflects its true worth, this article walks through the key signals that matter for value focused investors. The stock last closed at US$45.14, with a recent return of 8.0% over 7 days and 8.4% over 30 days, set against an 11.4% return year to date and a 25.4% decline over the past year. These moves sit against a backdrop of ongoing interest in medical devices and surgical technologies. Investors are watching how companies like CONMED...

If you are wondering whether Corcept Therapeutics at around US$34.82 is starting to look interesting on price, you are not alone. The stock has been drawing attention from investors focused on value. The share price has seen a 12.9% decline over the last 7 days, 20.8% over 30 days, 8.8% year to date and 45.2% over 1 year, even though the 3 year and 5 year returns sit at 63.4% and 38.4% respectively. Recent coverage has largely centered on ongoing developments in its pharmaceutical and...

Blackstone (NYSE:BX) has agreed to acquire Champions Group, a multi-service home services platform. Blackstone Infrastructure has received Federal Energy Regulatory Commission approval for its planned acquisition of TXNM Energy. Both moves expand Blackstone’s presence in essential services and energy infrastructure businesses. For you as an investor, these updates highlight how Blackstone is putting capital to work in areas tied to everyday needs, from home services to energy transmission...

Earlier this week, Markel Group’s insurance operations announced a collaboration with cyber risk specialist Upfort to offer eligible U.S. cyber policyholders access to Upfort Shield, an AI‑powered, multi‑layer defense platform and endpoint detection tools aimed at helping reduce cyberattack risks. This move deepens Markel’s service offering in cyber insurance by pairing coverage with embedded risk‑prevention technology for middle‑market businesses, potentially strengthening customer...

Akamai Technologies recently reported fourth-quarter 2025 results showing revenue of US$1,094.91 million and full-year 2025 revenue of US$4,208.18 million, alongside lower net income and earnings per share compared with the prior year. At the same time, the company issued 2026 guidance calling for higher capital spending and projecting revenue of US$1,060 million to US$1,085 million for the first quarter and US$4.40 billion to US$4.55 billion for the full year, as it invests heavily in its...

If you are looking at Cleveland-Cliffs and wondering whether the recent share price really reflects the value of the business, this article will walk through what the numbers are saying. The stock last closed at US$10.65, with returns of 2.6% over 7 days, a 29.4% decline over 30 days, and year to date and 1 year returns of 21.7% and 6.2% declines respectively, while the 3 year and 5 year returns are 46.0% and 20.2% declines. These moves sit against a broader backdrop of ongoing interest in...

XPeng (NYSE:XPEV) has launched a unified global in-app charging payment solution through a new partnership with Antom. The rollout begins outside mainland China with coverage in Hong Kong and planned expansion into Southeast Asia. The service enables cross-border, multi-currency payments for electric vehicle charging within XPeng's ecosystem. XPeng, an electric vehicle maker listed on the NYSE under ticker XPEV, is expanding its charging and software ecosystem as global EV adoption scales...

Natera recently attracted positive attention after Duquesne Family Office highlighted the company’s strong oncology testing momentum, including 54% growth in third-quarter oncology volumes and expanding use of its Signatera molecular residual disease blood test, which now represents nearly a quarter of total tests. While Natera remains unprofitable, its recurring revenue base, cash generation and scalable diagnostics platform across women’s health, oncology and organ health are drawing...

If you are wondering whether Doximity is starting to look like value or is still priced for high expectations, you are in the right place to assess what the current share price really reflects. The stock most recently closed at US$25.55, after a 2.1% move over the past week, but with much steeper returns of a 37.1% decline over 30 days, a 41.0% decline year to date, and a 64.7% decline over the past year. These sharp price moves have come alongside ongoing discussion about Doximity's role as...

If you are wondering whether Scholar Rock Holding's recent share price puts it on sale or already prices in a lot of optimism, you are asking the right question for a valuation focused look at the stock. The shares recently closed at US$48.00, with returns of 4.4% over 7 days, 8.4% over 30 days, 12.1% year to date, 27.3% over 1 year, a very large gain over 3 years, and a 11.3% decline over 5 years. This naturally raises questions about how much upside or risk is now built into the...

Earlier this week, UBS upgraded BlackRock to Buy after the asset manager reported strong fourth‑quarter results and highlighted a solid start to first‑quarter fund flows at the UBS Financials conference. This shift in analyst stance comes even as BlackRock manages headwinds such as outflows from its Bitcoin ETFs and concerns around private market liquidity, underlining how its broader business mix is shaping perceptions. We’ll now examine how UBS’s more positive view on BlackRock’s earnings...

Taylor Morrison Home recently launched its “Homes Built for Real Life” brand platform, highlighting authentic everyday living, while also reporting full-year 2025 revenue of US$8,121.48 million and net income of US$782.5 million, alongside a larger, extended share repurchase authorization through 2027. The combination of a consumer research-driven brand aimed at millennial and Gen Z buyers and an upsized US$1,000 million buyback plan underscores how Taylor Morrison is aligning its marketing,...

Why Abbott Laboratories (ABT) is Back on Investors’ Radar Abbott Laboratories (ABT) is drawing fresh attention after recent share price moves, with the stock roughly flat over the past week but showing a gain over the past month and weaker returns over the past year. See our latest analysis for Abbott Laboratories. At a share price of US$112.21, Abbott’s recent 4.46% 1 month share price return contrasts with its weaker year to date share price performance and a 15.27% 1 year total shareholder...

If you are looking at AMETEK and wondering whether the current price really reflects its underlying worth, you are not alone. The stock last closed at US$233.51, with returns of 1.6% over 7 days, 5.8% over 30 days, 11.7% year to date, 26.3% over 1 year, 69.0% over 3 years, and 104.5% over 5 years. This naturally raises questions about how much future potential or risk is already priced in. Recent coverage around AMETEK has focused on its role in the capital goods space and how investors are...

Targa Resources Corp. recently reported 2025 results showing revenue of US$17.03 billion and net income of US$1.92 billion, while also outlining extensive new gas processing and NGL infrastructure projects across the Permian and Gulf Coast that are scheduled to come online through 2028. The company coupled this with a planned 25% increase in its 2026 annual common dividend per share to US$5.00, underpinned by record volumes, expanding processing and fractionation capacity, and ongoing share...

Pool (POOL) has attracted investor attention after recent share price moves, with the stock showing a 1 day gain of 1.49% but negative returns over the past week and month. See our latest analysis for Pool. That 1 day share price gain sits against weaker momentum, with a 7 day share price return of 16.63% and a 30 day share price return of 16.38%. The 1 year total shareholder return of 34.66% and 5 year total shareholder return of 29.70% point to sustained pressure rather than a recent...

Blackstone Mortgage Trust (BXMT) just paired a change in its finance leadership with fresh earnings and a completed share repurchase program, giving investors several new data points to assess the stock’s risk and income profile. See our latest analysis for Blackstone Mortgage Trust. At a share price of $19.52, Blackstone Mortgage Trust has seen a 1-day share price return of 1.24%, a 30-day share price return of 2.52%, and a 1-year total shareholder return of 5.28%. These developments around...

Madrigal Pharmaceuticals (MDGL) is back in focus after reporting full-year 2025 results, combining nearly US$1 billion in Rezdiffra sales with a net loss of US$288.28 million and an improving per-share loss. See our latest analysis for Madrigal Pharmaceuticals. The recent full year 2025 update comes after a sharp pullback in the share price, with a 30 day share price return of 9.46% and a 90 day share price return of a 26.52% decline. However, longer term total shareholder returns of 35.04%...